Receptor imaging in oncology by means of nuclear medicine: Current status

Journal of Clinical Oncology

Volumn 22, Issue 17, 2004, Pages 3593-3607

  Van Den Bossche, Bieke ^a   Van de Wiele, Christophe ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBON 11; CELL SURFACE RECEPTOR; FLUORINE 18; GALLIUM 68; INDIUM 111; IODINE 123; OCTREOTIDE; OXYGEN 15; PENTETATE INDIUM IN 111; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; ESTROGEN RECEPTOR;

COMPUTER ASSISTED TOMOGRAPHY; DECISION MAKING; DRUG DISTRIBUTION; HUMAN; IMAGE ANALYSIS; IN VIVO STUDY; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE; ONCOLOGY; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; NEOPLASM; SCINTISCANNING;

HUMANS; NEOPLASMS; RADIOPHARMACEUTICALS; RECEPTORS, CELL SURFACE; RECEPTORS, ESTROGEN; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 4444383332     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.10.216     Document Type: Review

References (100)

1. Eberl S, Zimmerman RE: Nuclear medicine imaging instrumentation, in Muray IPC, EII PJ (eds): Nuclear Medicine in Clinical Diagnosis and Treatment. Edinburgh, Churchill Livingstone, 1998, pp 1559-1569
2. Bailey DL, Parker JA: Single photon emission computed tomography, in Muray IPC, Ell PJ (eds): Nuclear Medicine in Clinical Diagnosis and Treatment. Edinburgh, Churchill Livingstone, 1998, pp 1589-1601
3. Meikle SR, Dahlbom M: Positron emission tomography, in Muray IPC, Ell PJ (eds): Nuclear Medicine in Clinical Diagnosis and Treatment. Edinburgh, Churchill Livingstone, 1998, pp 1603-1616
4. Boyd RE, Silvester DJ: Radioisotope production, in Muray IPC, Ell PJ (eds): Nuclear Medicine in Clinical Diagnosis and Treatment. Edinburgh, Churchill Livingstone, 1998, pp 1617-1624
5. Okarvi SM: Recent developments in 99Tcm-labelled peptide-based radiopharmaceuticals: An overview. Nucl Med Commun 20:1093-1112, 1999
6. Eckelman WC: The testing of putative receptor binding radiotracers in vivo, in Diksic M, Reba RC (eds): Radiopharmaceuticals and Brain Pathology Studies With PET and SPECT. Boca Raton, FL, CRC Press, 1982. pp 42-62
7. Vera DR, Krohn KA, Scheibe PO, et al: Identifiability analysis of an in vivo receptor-binding radiopharmacokinetic system. IEEE Trans Biomed Eng 32:312-322, 1985
8. McElvany KD, Katzenellebogen JA, Shafer KE, et al: 16-alpha-(77Br) Bromoestradiol-17-beta: Dosimetry and preliminary clinical studies. J Nucl Med 23:425-430, 1982
9. Preston DF, Spicer JA, Baranvzuk C, et al: Clinical results of breast cancer detection by imageable estradiol (1-123 E2). Eur J Nucl Med 16:430, 1990(abstr 159)
10. Schober O, Schicha H, Reiners C, et al: Breast cancer imaging with radioiodinated oestradiol. Lancet 335:1522, 1990
11. Scheidhauer K, Müller S, Smolarz K, et al: Tumor-szintigraphie mit 123J-markiertem östradiol beim mammakarzinom-rezeptorszintigraphie. Nuklearmedizin 30:84-99, 1991
12. Kenady DE, Pavlik EJ, Nelson K, et al: Images of estrogen-receptor- positive breast tumors produced by estradiol labeled with iodine I 123 at 16 alpha. Arch Surg 128:1373-1381, 1993
13. Mintun MA, Welch MJ, Siegel BA, et al: Breast cancer: PET imaging of estrogen receptors. Radiology 169:45-48, 1988
14. McGuire AH, Dehdashti F, Siegel BA, et al: Positron tomographic assessment of α-(18F)fluoro 17β-estradiol uptake in metastatic breast carcinoma. J Nucl Med 32:1526-1531, 1991
15. Dehdashti F, Mortimer JE, Siegele BA, et al: Positron tomographic assessment of estrogen receptors in breast cancer: Comparison with FDG-PET and in vitro receptor assays. J Nucl Med 36:1766-1774, 1995
16. Mortimer JE, Dehdashti F, Siegel BA, et al: Clinical correlation of FDG and FES-PET imaging with estrogen receptors in breast cancer and response to systemic therapy. Clin Cancer Res 2:933-939, 1996
17. Mortimer JE, Dehdashti F, Siegel BA, et al: Metabolic flair: Indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 19:2797-2803, 2001
18. Mankoff DA, Tewson TJ, Peterson LM, et al: The heterogeneity of estrogen receptor expression in metastatic breast cancer as measured by [18F]-fluoroestradiol PET. J Nucl Med 41:28P, 2000 (abstr 108)
19. Ribeiro-Barras MJ, Foulon C, Baulieu JL, et al: Estrogen receptor imaging with 17 alpha-[123I]iodovinyl-11 beta-methoxyestradiol (MIVE2), part II: Preliminary results in patients with breast carcinoma. Int J Rad Appl Instrum B 19:263-267, 1992
20. Rijks LJM, Bakker PJM, van Tienhoven G, et al: Imaging of estrogen receptors in primary and metastatic breast cancer patients with iodine-123-labeled Z-MIVE. J Clin Oncol 15:2536-2545, 1997
21. Nachar O, Rousseau JA, Lefebvre B, et al: Biodistribution, dosimetry and metabolism of 11 beta-methoxy-(17alpha,20 E/Z)-[123I]iodovinylestradiol in healthy women and breast cancer patients. J Nucl Med 40:1728-1736, 1999
22. Bennink RJ, Rijks LJ, van Tienhoven G, et al: Estrogen receptor status in primary breast cancer: Iodine 123-labeled cis-11 beta-methoxy-17alpha-iodovinyl estradiol scintigraphy. Radiology 220:774-779, 2001
23. Bennink RJ, van Tienhoven G, Rijks LJ, et al: In vivo prediction of response to antiestrogen treatment in estrogen receptor-positive breast cancer. J Nucl Med 45:1-7, 2004
24. Bertolessi A, Cartei G, Turin D, et al: Behaviour of vaginal epithelial maturation and sex hormone binding globulin in post-menopausal breast cancer patients during the first year of tamoxifen therapy. Cytopathology 9:263-270, 1998
25. Rose DP, Chleboswki RT, Connolly JM, et al: Effects of tamoxifen adjuvant therapy and a low-fat diet on serum binding proteins and estradiol bioavailability in postmenopausal breast cancer patients. Cancer Res 52:5386-5390, 1992
26. Lonning PE, Johanessen DC, Lien EA, et al: Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients. J Steroid Biochem Mol Biol 52:491-496, 1995
27. Pasqualini JR, Schatz B, Varin C, et al: Recent data on estrogen sulfatases and sulfotransferases activities in human breast cancer. J Steroid Biochem Mol Biol 41:323-339, 1992
28. Pasqualini JR, Chetrite GS: Estrone sulfatase versus estrone sulfotransferase in human breast cancer: Potential clinical applications. J Steroid Biochem Mol Biol 69:287-292, 1999
29. Chetrite GS, Kloosterboer HJ, Philippe JC, et al: Effect of Org OD14 (LIVIAL) and its metabolites on human estrogen sulphotransferase activity in the hormone-dependent MCF-7 and T-47D, and the hormone-independent MDA-MB-231, breast cancer cell lines. Anticancer Res 19:269-275, 1999
30. Dehdashti F, Flanagan FL, Mortimer JE, et al: Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 26:976, 1999 (abstr OS-64)
31. Bennink R, Rijks L, van Tienhoven G, et al: Can Z-MIVE scintigraphy predict response to antiestrogen treatment in metastasized ER-positive breast cancer? Eur J Nucl Med 976, 1999 (abstr)
32. O'Brain CA, Liskamp RM, Solomon DH, et al: Inhibition of protein kinase C by tamoxifen. Cancer Res 45:2462-2465, 1985
33. Castoria G, Migliaccio A, Nola E, et al: In vitro interaction of estradiol receptor with Ca2+-calmodulin. Mol Endocrinol 2:167-174, 1988
34. Guvakova MA, Surmacz E: Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signalling pathway in breast cancer cells. Cancer Res 57:2606-2610, 1997
35. Delpassand ES, Yang DJ, Wallace S, et al: Synthesis, biodistribution, and estrogen receptor scintigraphy of indium-111-diethylenetriaminepentaacetic acid-tamoxifen analogue. J Pharm Sci 85:553-559, 1996
36. Yang DJ, Li C, Kuang LR, et al: Imaging, biodistribution and therapy potential of halogenated tamoxifen analogues. Life Sci 55:53-67, 1994
37. Inoue T, Kim EE, Wallace S, et al: Positron emission tomography using [18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: Preliminary study. Cancer Biother Radiopharm 11:235-245, 1996
38. Van de Wiele C, De Vos F, De Sutler J, et al: Biodistribution and dosimetry of (123-iodine)-iodomethyl-N,N-diethyl-tamoxifen: An (anti) oestrogen receptor radioligand for therapy efficacy prediction. Eur J Nucl Med 26:1259-1264, 1999
39. Van de Wiele C, Cocquyt V, VandenBroecke R, et al: Iodine-labeled tamoxifen uptake in primary human breast carcinoma. J Nucl Med 42:1818-1820, 2001
40. Katzenellenbogen JA: Designing steroid receptor-based radiotracers to image breast and prostate tumors. J Nucl Med 36:S8-S13, 1995 (suppl 6)
41. Van den Bos JC, Rijks LJM, van Doremalen PAPM, et al: New iodinated progestins as potential ligands for progesterone receptor imaging in breast cancer: Part 1. Synthesis and in vitro pharmacological characterization. Nucl Med Biol 25:781-789, 1998
42. Rijks UM, van den Bos JC, van Doremalen PAPM, et al: New iodinated progestins as potential ligands for progesterone receptor imaging in breast cancer: Part 2. In vivo pharmacological characterization. Nucl Med Biol 25:791-798, 1998
43. Liu AJ, Carlson KE, Katzenelenbogen JA: Synthesis of high-affinity fluorine-substituted ligands for the androgen receptor-potential agents for imaging prostatic-cancer by positron emission tomography. J Med Chem 35:2113-2129, 1992
44. Choe YS, Lidstrom PJ, Chi DY, et al: Synthesis of 11-beta-[F-18]fluoro-5- alpha-dihydrotestosterone and 11-beta-[F-18]fluoro-19-nor-5-alpha- dihydrotestosterone-preparation via halofluorination-reduction, receptor-binding, and tissue distribution. J Med Chem 38:816-825, 1995
45. Choe YS, Katenellenbogen JA: Synthesis of C-6 fluoroandrogens: Evaluation of ligands for tumor receptor imaging. Steroids 60:414-422, 1995
46. Bonasera T, Oneil JP, Xu M, et al: Pre-clinical evaluation of fluorine-18-labeled androgen receptor ligands in baboons. J Nucl Med 37:1009-1015, 1996
47. Serafini AN: From monoclonal antibodies to peptides and molecular recognition units: An overview. J Nucl Med 34:533-536, 1993
48. Reubi JC: Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24:389-427, 2003
49. Signore A, Annovazi A, Chianelli M, et al: Peptide radiopharmaceuticals for diagnosis and therapy. Eur J Nucl Med 28:1555-1565, 2001
50. Heppeler A, Froidevaux S, Eberle AN, et al: Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 7:971-994, 2000
51. Duncan JR, Stephenson MT, Wu HP, et al: Indium-111- diethyletriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal and hepatocyte lysosomes. Cancer Res 57:659-671, 1997
52. Reubi JC, Waser B, Schaer JC, et al: Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 28:836-846, 2001
53. Kwekkeboom DJ, de Herder WW, Krenning EP: Receptor imaging in the diagnosis and treatment of pituitary tumours. J Endocrinol Invest 22:80-88, 1999
54. Gibril F, Reynolds JC, Doppman JL, et al: Somatostatin receptor scintigraphy: Its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas - A prospective study. Ann Intern Med 125:26-34, 1996
55. Lebtahi R, Cadiot G, Sarda L, et al: Clinical impact of Somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 38:853-858, 1997
56. Termanini B, Gibril F, Reynolds JC, et al: Value of Somatostatin receptor scintigraphy: A prospective study of its effect on clinical management. Gastroenterology 112:335-347, 1997
57. Jensen RT, Gibril F: Somatostatin receptor scintigraphy in gastrinomas. Ital J Gastroenterol Hepatol 31:5179-5185. 1999 (suppl 2)
58. Kwekkeboom DJ, Krenning EP, Bakker WH, et al: Somatostatin analogue scintigraphy in carcinoid tumours. Eur J Nucl Med 20:283-292, 1993
59. Nilsson O, Kolby L, Wangberg B, et al: Comparative studies on the expression of Somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. Br J Cancer 77:632-637, 1998
60. Grufferman S, Gillman MW, Pasternak LR, et al: Familial carotid body tumours: Case reports and epidemiologic review. Cancer 46:2116-2122, 1980
61. Kwekkeboom DJ, Krenning EP: Somatostatin receptor imaging. Semin Nucl Med 32:84-91, 2002
62. Krenning EP, Kwekkeboom DJ, Bakker WH, et al: Somatostatin receptor scintigraphy with [11ln-DTPA-D-Phe1]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20:716-731, 1993
63. Berenger N, Moretti JL, Boaziz C, et al: Somatostatin receptor imaging in small cell lung cancer. Eur J Cancer 32A:1429-1431, 1996
64. Bohuslavizki KH, Brenner W, Gunther M, et al: Somatostatin receptor scintigraphy in the staging of small cell lung cancer. Nucl Med Commun 17:191-196, 1996
65. Kwekkeboom DJ, Kho GS, Lamberts SWJ, et al: The value of octreotide scintigraphy in patients with lung cancer. Eur J Nucl Med 21:1106-1113, 1994
66. Bombardieri E, Crippa F, Cataldo I, et al: Somatostatin receptor imaging of small cell lung cancer (SCLC) by means of 111In-DTPA-octreotide scintigraphy. Eur J Cancer 31A:184-188, 1995
67. Hoffman M, Maecke H, Borner R, et al: Biokinetics and imaging with the Somatostatin receptor PET radioligand (68)Ga-DOTATOC: Preliminary data. Eur J Nucl Med 28:1751-1757, 2001
68. Kowalski J, Henze M, Schuhmacher J, et al: Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-octreotide in comparison to [111In]-DTPAOC SPECT: First results in patients with neuroendocrine tumors. Mol Imaging Biol 5:42-48, 2003
69. Blum J, Handmaker H, Lister-James J, et al: A multicenter trial with a Somatostatin analog 99mTc depreotide in the evaluation of solitary pulmonary nodules. Chest 117:1232-1238, 2000
70. Lebtahi R, Le Cloirec J, Houzard C, et al: Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with 111In-pentreotide scintigraphy. J Nucl Med 43:889-895, 2002
71. Plachcinska A, Mikolajczak R, Maecke HR, et al: 99mTc-EDDA/HYNIC-TOC scintigraphy in the differential diagnosis of solitary pulmonary nodules. Eur J Nucl Med Mol Imaging 10.1007/S00259-004-1511-3
72. Gabriel M, Decristoforo C, Donnemiller E, et al: An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med 44:708-716, 2003
73. Van Hagen PM, Krenning EP, Reubi JC, et al: Somatostatin analogue scintigraphy of malignant lymphoma. Br J Haematol 83:75-79, 1993
74. Leners N, Jamar F, Fiasse R, et al: Indium-111 pentreotide uptake in endocrine tumors and lymphoma. J Nucl Med 37:916-922, 1996
75. van den Anker-Lugtenburg PJ, Lowenberg B, Lamberts SW, et al: The relevance of somatostatin receptor expression in malignant lymphomas. Metabolism 45:96-97, 1996 (suppl 1)
76. Lugtenburg PJ, Krenning EP, Valkema R, et al: Somatostatin receptor scintigraphy useful in stage I-II Hodgkin's disease: More extended disease identified. Br J Haematol 112:936-944, 2001
77. Schmidt M, Scheidhauer K, Luyken C, et al: Somatostatin receptor imaging in intracranial tumours. Eur J Nucl Med 25:675-686, 1998
78. Haldemann AR, Rösler H, Barth A, et al: Somatostatin receptor scintigraphy in patients with CNS tumors: The role of blood brain barrier permeability. J Nucl Med 36:403-410, 1995
79. Van Eijck CH, Krenning EP, Bootsma A, et al: Somatostatin receptor scintigraphy in primary breast cancer. Lancet 343:640-643, 1994
80. Erspamer V: Discovery, isolation and characterisation of bombesin-like peptides. Ann N Y Acad Sci 547:3-9, 1988
81. Nelson J, Donelly M, Walker B, et al: Bombesin stimulates proliferation of human breast cancer cells in culture. Br J Cancer 63:933-936, 1991
82. Moody TW, Cuttitta F: Growth factor and peptide receptors in small cell lung cancer. Life Sci 52:1161-1173, 1993
83. Moody TW, Leyton J, Garcia-Marin L, et al: Nonpeptide gastrin releasing peptide receptor antagonists inhibit the proliferation of lung cancer cells. Eur J Pharmacol 474:21-29, 2003
84. Miyazaki M, Lamharzi N, Schally AV, et al: Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin/gastrin- releasing peptide (GRP) antagonists RC-3940-II and RC-3095. Eur J Cancer 34:710-717, 1998
85. Gugger M, Reubi JC: Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am J Pathol 155:2067-2076, 1999
86. Markwalder R, Reubi JC: Gastrin-releasing peptide receptors in the human prostate: Relation to neoplastic transformation. J Cancer Res 39:1152-1159, 1999
87. Fathi Z, Way JW, Corjay MH, et al: Bombesin receptor structure and expression in human lung carcinoma cell lines. J Cell Biochem 24:237-246, 1996 (suppl)
88. Preston SR, Woodhouse LF, Jones-Blackett S, et al: High affinity binding sites for gastrin-releasing peptide on human colorectal cancer tissue but not uninvolved mucosa. Br J Cancer 71:1087-1089, 1995
89. Preston SR, Woodhouse LF, Jones-Blackett S, et al: High affinity binding sites for gastrin releasing peptide on human gastric cancer and Menetrier's mucosa. Cancer Res 53:5090-5092, 1993
90. Mahmoud S, Staley J, Taylor J, et al: (Psi13,14) bombesin analogues inhibit growth of small cell lung cancer in vitro and in vivo. Cancer Res 51:1798-1802, 1991
91. Milovanovic SR, Radulovic S, Groot K, et al: Inhibition of growth of PC-82 human prostate cancer cell line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist (D-Trp6)-luteinizing hormone-releasing hormone and somatostatin analogue RC-160. Prostate 20:269-280, 1992
92. Orosz A, Schreit J, Nagy J, et al: New short-chain analogues of a substance-P antagonist inhibit proliferation of human small-cell lung-cancer cells in vitro and in vivo. Int J Cancer 60:82-87, 1995
93. Serially AV, Nagy A: Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumours. Eur J Endocrinol 141:1-14, 1999
94. Kelley MJ, Linnoila RI, Avis IL, et al: Anti-tumour activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. Chest 112:256-261, 1997
95. Davis TP, Crowell S, Taylor J, et al: Metabolic stability and tumor inhibition of bombesin/GRP receptor antagonist. Peptides 13:401-407, 1992
96. 2 in ovarian carcinoma induced to express the gastrin releasing peptide receptor by adenoviral vector-mediated gene transfer. J Nucl Med 38:1221-1229, 1997
97. Breeman W, de Jong M, Bernard BF, et al: Pre-clinical evaluation of (111)In-DTPA-Pro(1), Tyr(4)bombesin, a new radioligand for bombesin-receptor scintigraphy. Int J Cancer 83:657-663, 1999
98. Nock B, Nikolopoulou A, Chiotellis E, et al: [(99m)Tc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med Mol Imaging 30:247-258, 2003
99. Van de Wiele C, Dumont F, Vanden Broecke R, et al: Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: A feasibility study. Eur J Nucl Med 27:1694-1699, 2000
100. Reubi JC, Waser B: Unexpected high incidence of cholecystokinin/gastrin receptors in human medullary thyroid carcinomas. Int J Cancer 67:644-647, 1996